RxDoctor Payments Data

Moises Harari Turquie, MD

Hematology & Oncology · Albuquerque, NMNPI 1073963203

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.2% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 9 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in NM, where the typical reported total is $2,649.

$885in general payments, 2019–2025

Across 9 payments — averaging $98.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$150
  • Sanofi$130
  • Novartis$112
  • Pfizer$110
  • Seagen Inc.$97
  • Gilead$97
  • plus $189 from 3 others
$274,346in research payments, 2019–2025

Across 16 payments — averaging $17,147 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • E.r. Squibb & Sons, L.L.C.$111K
  • Eli Lilly$65K
  • Janssen Research & Development, LLC$64K
  • Merck$33K

What the payments were for

  • Food & beverage$80791%
  • Education$789%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$885 in reported general payments places this provider in the 25th percentile of 54 hematology & oncology providers in New Mexico.

See all hematology & oncology providers in New Mexico

Medicare billing

Part B allowed, 2024
$28,227
Medicare patients
99
Services billed
380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone Hcl27$338
Ondansetron Hcl25$223
Levothyroxine Sodium27$196
Gabapentin15$177

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →